[go: up one dir, main page]

NO20075154L - Formuleringer av en src/abl-inhibitor - Google Patents

Formuleringer av en src/abl-inhibitor

Info

Publication number
NO20075154L
NO20075154L NO20075154A NO20075154A NO20075154L NO 20075154 L NO20075154 L NO 20075154L NO 20075154 A NO20075154 A NO 20075154A NO 20075154 A NO20075154 A NO 20075154A NO 20075154 L NO20075154 L NO 20075154L
Authority
NO
Norway
Prior art keywords
src
formulations
abl inhibitor
pharmaceutical compositions
abl
Prior art date
Application number
NO20075154A
Other languages
English (en)
Other versions
NO343939B1 (no
Inventor
Julia Zh Gao
Rajeshwar Motheram
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37076246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075154(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20075154L publication Critical patent/NO20075154L/no
Publication of NO343939B1 publication Critical patent/NO343939B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår farmasøytiske preparater av 'N-(2-klor-6-metylfenyl)-2-[[6-[4-(2-hydroksyetyl)-1-piperazinyl]-2-metyl-4-pyrimidinyl]amino]-5-tiazolkarboksamid og metoder for anvendelse av de farmasøytiske preparater ved behandling av onkologiske og immunologiske lidelser.
NO20075154A 2005-05-05 2007-10-10 Formuleringer av en src/abl-inhibitor NO343939B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67803005P 2005-05-05 2005-05-05
PCT/US2006/017073 WO2006121742A2 (en) 2005-05-05 2006-05-04 Formulations of a src/abl inhibitor

Publications (2)

Publication Number Publication Date
NO20075154L true NO20075154L (no) 2008-02-01
NO343939B1 NO343939B1 (no) 2019-07-15

Family

ID=37076246

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075154A NO343939B1 (no) 2005-05-05 2007-10-10 Formuleringer av en src/abl-inhibitor

Country Status (18)

Country Link
US (2) US20060251723A1 (no)
EP (1) EP1885339B1 (no)
JP (1) JP5173794B2 (no)
CN (2) CN102813655A (no)
AR (1) AR054445A1 (no)
DK (1) DK1885339T3 (no)
ES (1) ES2546847T3 (no)
GE (1) GEP20104927B (no)
HR (1) HRP20151051T1 (no)
HU (1) HUE026040T2 (no)
NO (1) NO343939B1 (no)
PE (1) PE20061373A1 (no)
PL (1) PL1885339T3 (no)
PT (1) PT1885339E (no)
RS (1) RS54258B1 (no)
SI (1) SI1885339T1 (no)
TW (1) TWI386205B (no)
WO (1) WO2006121742A2 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID30460A (id) 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
PT1885339E (pt) 2005-05-05 2015-10-12 Bristol Myers Squibb Holdings Ireland Formulações de um inibidor src/abl
WO2006135790A1 (en) * 2005-06-09 2006-12-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
EP1937270A1 (en) * 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
EP2132173B1 (en) * 2007-02-26 2015-10-07 Merck Sharp & Dohme Corp. Formulations for cathepsin k inhibitors
EP2359813A1 (en) 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
CN101891738B (zh) 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
JP5589097B2 (ja) * 2010-02-08 2014-09-10 南京▲か▼文迪許生物工程技術有限公司 ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
CN104274420B (zh) * 2013-07-11 2019-03-05 石药集团中奇制药技术（石家庄）有限公司 一种达沙替尼组合物及其制备方法
IN2013MU03610A (no) 2013-12-18 2015-04-24 Dharmesh Mahendrabhai Shah
EP3419605A1 (en) 2016-02-25 2019-01-02 Remedica Ltd Dasatinib formulation
JP7166754B2 (ja) 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
JP7249397B2 (ja) * 2017-12-27 2023-03-30 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
WO2020018053A2 (en) * 2018-05-25 2020-01-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi The tablet comprising dasatinib
TWI770624B (zh) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
GB2592680A (en) 2020-03-06 2021-09-08 Zentiva Ks Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof
EP4071248A1 (en) 2021-04-07 2022-10-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Means and methods for enhancing receptor-targeted gene transfer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539380A (en) 1968-01-08 1970-11-10 Upjohn Co Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US5681382A (en) 1995-08-22 1997-10-28 Shin-Etsu Chemical Co., Ltd. Rapidly soluble coating composition and method for preparing same
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
ID30460A (id) 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050215795A1 (en) * 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
PT1885339E (pt) 2005-05-05 2015-10-12 Bristol Myers Squibb Holdings Ireland Formulações de um inibidor src/abl

Also Published As

Publication number Publication date
RS54258B1 (sr) 2016-02-29
EP1885339A2 (en) 2008-02-13
CN102813655A (zh) 2012-12-12
EP1885339B1 (en) 2015-07-29
JP5173794B2 (ja) 2013-04-03
WO2006121742A3 (en) 2007-02-22
US20130122093A1 (en) 2013-05-16
WO2006121742A2 (en) 2006-11-16
HUE026040T2 (en) 2016-05-30
PT1885339E (pt) 2015-10-12
ES2546847T3 (es) 2015-09-29
DK1885339T3 (en) 2015-10-19
NO343939B1 (no) 2019-07-15
HRP20151051T1 (hr) 2015-11-06
CN101170996A (zh) 2008-04-30
JP2008540440A (ja) 2008-11-20
AR054445A1 (es) 2007-06-27
TW200716117A (en) 2007-05-01
PL1885339T3 (pl) 2015-12-31
SI1885339T1 (sl) 2015-10-30
GEP20104927B (en) 2010-03-25
US20060251723A1 (en) 2006-11-09
PE20061373A1 (es) 2006-12-15
TWI386205B (zh) 2013-02-21

Similar Documents

Publication Publication Date Title
NO20075154L (no) Formuleringer av en src/abl-inhibitor
NO20075087L (no) Kombinasjoner, metoder og sammensetninger for behandling av cancer
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
TW200700416A (en) 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EP1943348A4 (en) COMPOSITIONS, METHODS AND KITS FOR THE AMPLIFICATION OF NUCLEIC ACIDS
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
NO20084924L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
DE602006020773D1 (de) Als inhibitoren von beta-sekretase (bace) geeignete 2-amino-3,4-dihydropyridoä3,4-düpyrimidinderivate
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
DK1828151T3 (da) Malonamidderivater som inhibitorer af gamma-sekretase til behandlingen af alzheimer's sygdom
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
NO20084190L (no) Anvendelse av VX-702 til behandling av revmatoid artritt
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
CY1116766T1 (el) Σκευασματα αναστολεα της src/abl
BRPI0614481A2 (pt) composto, composição farmecêutica, uso do composto, e, método de tratamento de distúrbios mediados por mglur5
NO20091619L (no) Nye tetracykliske inhibitorer av cystein-proteaser, farmasoytiske blandinger derav og deres farmasoytiske anvendelse
WO2008093221A3 (en) Pharmaceutical compositions containing pde4 inhibitor for the treatment of inflammatory and allergic disorders

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMI, CH